Merck acquires antivirals developer Cidara Therapeutics
Merck (MSD outside of the US and Canada) has acquired Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion.
Cidara’s lead candidate, CD388, consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed to prevent influenza A and B.
CD388 is currently being evaluated in the Phase III ANCHOR study among adult and adolescent participants who are at higher risk of developing complications from influenza.
Supported by results from the Phase IIb NAVIGATE study, the US Food and Drug Administration (FDA) granted CD388 Breakthrough Therapy Designation.
“We continue to execute our science-led business development strategy, augmenting our pipeline with CD388, a potentially first-in-class, long-acting antiviral designed to prevent influenza in individuals at higher risk of complications,” said Robert Davis, Chairman and Chief Executive Officer, Merck. “We intend to build on the Cidara team’s remarkable progress and are confident that CD388 has the potential to be another important driver of growth through the next decade, creating real value for shareholders.”
“This milestone represents a transformational moment for Cidara and for our mission to redefine influenza prevention,” added Jeffrey Stein, President and Chief Executive Officer of Cidara. “Thanks to the extraordinary dedication of our team, the Phase IIb NAVIGATE study delivered compelling results that demonstrate CD388’s potential to provide an additional option to vaccines and antivirals to help address unmet needs in influenza prevention. Merck’s global development, regulatory and commercial capabilities provide the expertise and resources needed to bring this important innovation to those individuals who need it most.”
Diana Turner, Deputy Editor, DDW
